IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023

Aggregated presentation by day and by market

Name of issuer Identification code of issuer (Legal Entity Identifier) Day of transaction Identification code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares * Market (MIC Code)
IPSEN 549300M6SGDPB4Z94P11 10/07/2023 FR0010259150 511 108.65 AQEU
IPSEN 549300M6SGDPB4Z94P11 10/07/2023 FR0010259150 2,536 108.53 CEUX
IPSEN 549300M6SGDPB4Z94P11 10/07/2023 FR0010259150 507 108.55 TQEX
IPSEN 549300M6SGDPB4Z94P11 10/07/2023 FR0010259150 5,255 108.55 XPAR
IPSEN 549300M6SGDPB4Z94P11 11/07/2023 FR0010259150 878 109.08 AQEU
IPSEN 549300M6SGDPB4Z94P11 11/07/2023 FR0010259150 1,402 108.94 CEUX
IPSEN 549300M6SGDPB4Z94P11 11/07/2023 FR0010259150 633 108.97 TQEX
IPSEN 549300M6SGDPB4Z94P11 11/07/2023 FR0010259150 5,387 109.00 XPAR
IPSEN 549300M6SGDPB4Z94P11 12/07/2023 FR0010259150 666 108.65 AQEU
IPSEN 549300M6SGDPB4Z94P11 12/07/2023 FR0010259150 1,451 108.65 CEUX
IPSEN 549300M6SGDPB4Z94P11 12/07/2023 FR0010259150 782 108.68 TQEX
IPSEN 549300M6SGDPB4Z94P11 12/07/2023 FR0010259150 3,640 108.63 XPAR
IPSEN 549300M6SGDPB4Z94P11 13/07/2023 FR0010259150 145 110.02 CEUX
IPSEN 549300M6SGDPB4Z94P11 13/07/2023 FR0010259150 790 110.02 XPAR
IPSEN 549300M6SGDPB4Z94P11 14/07/2023 FR0010259150 235 110.67 AQEU
IPSEN 549300M6SGDPB4Z94P11 14/07/2023 FR0010259150 242 110.46 CEUX
IPSEN 549300M6SGDPB4Z94P11 14/07/2023 FR0010259150 65 110.58 TQEX
IPSEN 549300M6SGDPB4Z94P11 14/07/2023 FR0010259150 1,358 110.48 XPAR
             
* Two-digit rounding after the decimal   TOTAL 26,483 108.91  

 

 

Attachment



EN
18/07/2023

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...

12h 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour...

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec altération de BRAF, quel que soit le type d’altération BRAF.iLa décision s’appuie sur les données de l’étude pivot de Phase II FIREFLY1, qui a démontré des réponses tumorales urables et clini...

12h 1 EN
Free Trial
IPN IPSEN SA

Ipsen: 1 director

A director at Ipsen sold 3,800 shares at 158.200EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

02/24/26 February 24, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment

February 19, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publie ses comptes consolidés 2025

Ipsen S.A. publie ses comptes consolidés 2025 Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe

February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch